We are live on ! Find out more
ZYBT

Zhengye Biotechnology Holding

8 hedge funds and large institutions have $68.1K invested in Zhengye Biotechnology Holding in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 88 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.04% less ownership

Funds ownership: 0.26%0.21% (-0.04%)

40% less capital invested

Capital invested by funds: $113K → $68.1K (-$44.9K)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
8
Holders Change
Holders Change %
0%
% of All Funds
0.1%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
1
Reduced
3
Closed
1
Calls
Puts
Net Calls
Net Calls Change

ZYBT Hedge Fund Activity: Q2 2026 in Review

8 of the 8,320 institutional investors tracked by Wall St. Rank reported a position in Zhengye Biotechnology Holding (ZYBT) for Q2 2026, worth a combined $68.1K — down 40% from $113K a quarter earlier.

Fund positioning in ZYBT was balanced in Q2 2026: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 3 trimmed.

The largest buyer was XTX Topco, adding an estimated $4.22K. The largest seller was Winton Group, cutting an estimated $18.5K.

  • 8 institutional investors held Zhengye Biotechnology Holding (ZYBT) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $68.1K of Zhengye Biotechnology Holding stock for Q2 2026, down 40% quarter-over-quarter.
  • 1 fund opened new Zhengye Biotechnology Holding positions in Q2 2026 and 1 closed out, a net change of 0 holders.
  • The largest Zhengye Biotechnology Holding buyer in Q2 2026 was XTX Topco, an estimated $4.22K added.
  • The largest Zhengye Biotechnology Holding seller in Q2 2026 was Winton Group, an estimated $18.5K sold.

Based on aggregated 13F filings for Q2 2026.